Info@ThinkPinkRocks.org

Oncolytics Biotech Inc. (“Oncolytics”) today announced that it has submitted applications for Orphan Designation to the European Medicines Agency (“EMA”) for REOLYSIN® for the treatment of pancreatic and ovarian cancers.

Continued here:
Oncolytics Biotech submits Orphan Designation to EMA for treatment of ovarian, pancreatic cancers

Scroll to Top